The experimental power of FR900359 to study Gq-regulated biological processes

Nature Communications

Volumn 6, Issue , 2015, Pages

  Schrage, Ramona ^a   Schmitz, Anna Lena ^a   Gaffal, Evelyn ^a   Annala, Suvi ^a   Kehraus, Stefan ^a   Wenzel, Daniela ^a   Büllesbach, Katrin M ^a   Bald, Tobias ^a   Inoue, Asuka ^b,c   Shinjo, Yuji ^b   Galandrin, Ségolène ^d   Shridhar, Naveen ^a   Hesse, Michael ^a   Grundmann, Manuel ^a   Merten, Nicole ^a   Charpentier, Thomas H ^e   Martz, Matthew ^e   Butcher, Adrian J ^f   Slodczyk, Tanja ^a   Armando, Sylvain ^g   Effern, Maike ^a   Namkung, Yoon ^g   Jenkins, Laura ^h   Horn, Velten ⁱ   Stößel, Anne ^a   Dargatz, Harald ^a   Tietze, Daniel ⁱ   Imhof, Diana ^a   Gales, Céline ^d   Drewke, Christel ^a   Müller, Christa E ^a   Hölzel, Michael ^a   Milligan, Graeme ^h   Tobin, Andrew B ^f   Gomeza, Jesus ^a   Dohlman, Henrik G ^e   Sondek, John ^e   Harden, T Kendall ^e   Bouvier, Michel ^j   Laporte, Stéphane A ^g   Aoki, Junken ^b,k   Fleischmann, Bernd K ^a   Mohr, Klaus ^a   König, Gabriele M ^a   Tüting, Thomas ^a   Kostenis, Evi ^a   more..

^a UNIVERSITY OF BONN   (Germany)

^b TOHOKU UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d University Hospital of Toulouse   (France)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

^g RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^j INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^k JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLODEPSIPEPTIDE; FR 900359; GQ PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PERTUSSIS TOXIN; UNCLASSIFIED DRUG; DEPSIPEPTIDE; FR900359; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; ISOPROTEIN;

BIOACTIVITY; BIOCHEMISTRY; GENE EXPRESSION; INHIBITION; INHIBITOR; MAMMAL; PROBE; PROTEIN; SENSORY SYSTEM; TOXIN;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL LINE; MOLECULAR DYNAMICS; NONHUMAN; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASODILATATION; ANIMAL; ARDISIA; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR MODEL; MOUSE; PROTEIN CONFORMATION; TAIL; TUMOR CELL LINE; VASCULARIZATION;

MAMMALIA;

ANIMALS; ARDISIA; CELL LINE, TUMOR; DEPSIPEPTIDES; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HUMANS; MELANOMA; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; TAIL; VASOCONSTRICTION;

EID: 84984911801     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10156     Document Type: Article

References (70)

1. Pierce, K. L., Premont, R. T. & Lefkowitz, R. J. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3, 639-650 (2002).
2. Fredriksson, R., Lagerström, M. C., Lundin, L.-G. & Schiöth, H. B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 63, 1256-1272 (2003).
3. Milligan, G. & Kostenis, E. Heterotrimeric G-proteins: a short history. Br. J. Pharmacol. 147(Suppl 1): S46-S55 (2006).
4. Offermanns, S. G-proteins as transducers in transmembrane signalling. Prog. Biophys. Mol. Biol. 83, 101-130 (2003).
5. Simon, M. I., Strathmann, M. P. & Gautam, N. Diversity of G proteins in signal transduction. Science 252, 802-808 (1991).
6. Sprang, S. R. G protein mechanisms: insights from structural analysis. Annu. Rev. Biochem. 66, 639-678 (1997).
7. Hepler, J. R. & Gilman, A. G. G proteins. Trends Biochem. Sci. 17, 383-387 (1992).
8. Preininger, A. M. & Hamm, H. E. G protein signaling: insights from new structures. Sci. STKE 2004, re3 (2004).
9. Smrcka, A. V. Molecular targeting of Ga and Gbg subunits: a potential approach for cancer therapeutics. Trends Pharmacol. Sci. 34, 290-298 (2013).
10. Wright, B. D. et al. The lipid kinase PIP5K1C regulates pain signaling and sensitization. Neuron 82, 836-847 (2014).
11. Oldham, W. M. & Hamm, H. E. Heterotrimeric G protein activation by G-protein-coupled receptors. Nat. Rev. Mol. Cell Biol. 9, 60-71 (2008).
12. Nishimura, A. et al. Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule. Proc. Natl Acad. Sci. USA 107, 13666-13671 (2010).
13. Fujioka, M., Koda, S., Morimoto, Y. & Biemann, K. Structure of FR900359, a cyclic depsipeptide from Ardisia crenata sims. J. Org. Chem. 53, 2820-2825 (1988).
14. Hubbard, K. B. & Hepler, J. R. Cell signalling diversity of the Gqalpha family of heterotrimeric G proteins. Cell Signal. 18, 135-150 (2006).
15. Jones, J. C., and Jones., A. M., Temple, B. R. S. & Dohlman, H. G. Differences in intradomain and interdomain motion confer distinct activation properties to structurally similar Ga proteins. Proc. Natl Acad. Sci. USA 109, 7275-7279 (2012).
16. Loening, A. M., Wu, A. M. & Gambhir, S. S. Red-shifted Renilla reniformis luciferase variants for imaging in living subjects. Nat. Methods 4, 641-643 (2007).
17. Galés, C. et al. Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. Nat. Struct. Mol. Biol. 13, 778-786 (2006).
18. Saulière, A. et al. Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. Nat. Chem. Biol. 8, 622-630 (2012).
19. Ho, M. K. et al. Galpha(14) links a variety of G(i)- and G(s)-coupled receptors to the stimulation of phospholipase C. Br. J. Pharmacol. 132, 1431-1440 (2001).
20. Offermanns, S. & Simon, M. I. G alpha 15 and G alpha 16 couple a wide variety of receptors to phospholipase C. J. Biol. Chem. 270, 15175-15180 (1995).
21. Atwood, B. K., Lopez, J., Wager-Miller, J., Mackie, K. & Straiker, A. Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis. BMC Genom. 12, 14 (2011).
22. Gainetdinov, R. R., and Premont., R. T., Bohn, L. M., Lefkowitz, R. J. & Caron, M. G. Desensitization of G protein-coupled receptors and neuronal functions. Annu. Rev. Neurosci. 27, 107-144 (2004).
23. Rajagopal, S., Rajagopal, K. & Lefkowitz, R. J. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9, 373-386 (2010).
24. Kenakin, T. & Christopoulos, A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 12, 205-216 (2013).
25. Rajagopal, K., Lefkowitz, R. J. & Rockman, H. A. When 7 transmembrane receptors are not G protein-coupled receptors. J. Clin. Invest. 115, 2971-2974 (2005).
26. Butcher, A. J. et al. Concomitant action of structural elements and receptor phosphorylation determines arrestin-3 interaction with the free fatty acid receptor FFA4. J. Biol. Chem. 289, 18451-18465 (2014).
27. Mathiesen, J. M. et al. Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. Mol. Pharmacol. 68, 393-402 (2005).
28. Hudson, B. D. et al. The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Mol. Pharmacol. 84, 710-725 (2013).
29. Urban, J. D. et al. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320, 1-13 (2007).
30. Schröder, R. et al. Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat. Biotechnol. 28, 943-949 (2010).
31. Schröder, R. et al. Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat. Protoc. 6, 1748-1760 (2011).
32. Graham, R. M., and Perez., D. M., Hwa, J. & Piascik, M. T. Alpha 1-adrenergic receptor subtypes. Molecular structure, function, and signaling. Circ. Res. 78, 737-749 (1996).
33. Taniguchi, M. et al. YM-254890 analogues, novel cyclic depsipeptides with Galpha(q/11) inhibitory activity from Chromobacterium sp. QS3666. Bioorg. Med. Chem. 12, 3125-3133 (2004).
34. Henzler-Wildman, K. A. et al. Intrinsic motions along an enzymatic reaction trajectory. Nature 450, 838-844 (2007).
35. Alexander, N. S. et al. Energetic analysis of the rhodopsin-G-protein complex links the a5 helix to GDP release. Nat. Struct. Mol. Biol. 21, 56-63 (2014).
36. Coleman, D. E. et al. Structures of active conformations of Gi alpha 1 and the mechanism of GTP hydrolysis. Science 265, 1405-1412 (1994).
37. Schmitz, A.-L. et al. A cell-permeable inhibitor to trap Gaq proteins in the empty pocket conformation. Chem. Biol. 21, 890-902 (2014).
38. De Lean, A., Stadel, J. M. & Lefkowitz, R. J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J. Biol. Chem. 255, 7108-7117 (1980).
39. Schrage, R. et al. Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor. Br. J. Pharmacol. 169, 357-370 (2013).
40. O'Hayre, M. et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat. Rev. Cancer 13, 412-424 (2013).
41. Dorsam, R. T. & Gutkind, J. S. G-protein-coupled receptors and cancer. Nat. Rev. Cancer 7, 79-94 (2007).
42. Kang, T.-W. et al. Growth arrest and forced differentiation of human primary glioblastoma multiforme by a novel small molecule. Sci. Rep. 4, 5546 (2014).
43. Gilchrist, A., Li, A. & Hamm, H. E. G alpha COOH-terminal minigene vectors dissect heterotrimeric G protein signaling. Sci. STKE 2002, pl1 (2002).
44. Barren, B. & Artemyev, N. O. Mechanisms of dominant negative G-protein alpha subunits. J. Neurosci. Res. 85, 3505-3514 (2007).
45. Krumins, A. M. & Gilman, A. G. Targeted knockdown of G protein subunits selectively prevents receptor-mediated modulation of effectors and reveals complex changes in non-targeted signaling proteins. J. Biol. Chem. 281, 10250-10262 (2006).
46. Wettschureck, N. & Offermanns, S. Mammalian G proteins and their cell type specific functions. Physiol. Rev. 85, 1159-1204 (2005).
47. Katada, T. & Ui, M. Direct modification of the membrane adenylate cyclase system by islet-activating protein due to ADP-ribosylation of a membrane protein. Proc. Natl Acad. Sci. USA 79, 3129-3133 (1982).
48. Cassel, D. & Pfeuffer, T. Mechanism of cholera toxin action: covalent modification of the guanyl nucleotide-binding protein of the adenylate cyclase system. Proc. Natl Acad. Sci. USA 75, 2669-2673 (1978).
49. Chakraborty, M., Chatterjee, D., Kellokumpu, S., Rasmussen, H. & Baron, R. Cell cycle-dependent coupling of the calcitonin receptor to different G proteins. Science 251, 1078-1082 (1991).
50. Moriarty, T. M. et al. Go protein as signal transducer in the pertussis toxin-sensitive phosphatidylinositol pathway. Nature 343, 79-82 (1990).
51. Kaur, H., and Harris., P. W., Little, P. J. & Brimble, M. A. Total synthesis of the cyclic depsipeptide YM-280193, a platelet aggregation inhibitor. Org. Lett. 17, 492-495 (2015).
52. Rensing, D. T., Uppal, S., Blumer, K. J. & Moeller, K. D. Toward the selective inhibition of G Proteins: total synthesis of a simplified YM-254890 analog. Org. Lett. 17, 2270-2273 (2015).
53. Grace, M. S. et al. The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo. Br. J. Pharmacol. 171, 3881-3894 (2014).
54. 2+ influx and release. Mol. Pharmacol. 85, 758-768 (2014).
55. Jacobsen, S. E. et al. Delineation of the GPRC6A receptor signaling pathways using a mammalian cell line stably expressing the receptor. J. Pharmacol. Exp. Ther. 347, 298-309 (2013).
56. Copeland, R. A., Pompliano, D. L. & Meek, T. D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5, 730-739 (2006).
57. Vauquelin, G. & Charlton, S. J. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br. J. Pharmacol. 161, 488-508 (2010).
58. Nielsen, D. S. et al. Improving on nature: making a cyclic heptapeptide orally bioavailable. Angew. Chem. Int. Ed. Engl. 53, 12059-12063 (2014).
59. Chatterjee, J., Gilon, C., Hoffman, A. & Kessler, H. N-methylation of peptides: a new perspective in medicinal chemistry. Acc. Chem. Res. 41, 1331-1342 (2008).
60. Fu, D., Calvo, J. A. & Samson, L. D. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat. Rev. Cancer 12, 104-120 (2012).
61. Altucci, L. & Gronemeyer, H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer 1, 181-193 (2001).
62. Kohlmeyer, J. et al. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. Cancer Res. 69, 6265-6274 (2009).
63. Bald, T. et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 507, 109-113 (2014).
64. Voigtländer, U. et al. Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. Mol. Pharmacol. 64, 21-31 (2003).
65. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281-2308 (2013).
66. Inoue, A. et al. TGFα shedding assay: an accurate and versatile method for detecting GPCR activation. Nat. Methods 9, 1021-1029 (2012).
67. Hennen, S. et al. Decoding signaling and function of the orphan G proteincoupled receptor GPR17 with a small-molecule agonist. Sci. Signal. 6, ra93 (2013).
68. 3H]iperoxo. Biochem. Pharmacol. 90, 307-319 (2014).
69. Isom, D. G., and Marguet., P. R., Oas, T. G. & Hellinga, H. W. A miniaturized technique for assessing protein thermodynamics and function using fast determination of quantitative cysteine reactivity. Proteins 79, 1034-1047 (2011).
70. Yaktapour, N. et al. BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. J. Clin. Invest. 124, 5074-5084 (2014).